Guardant Health revenue and financials
$170.69Change from previous close: −8.83%Absolute change: −$16.53
In the fiscal year ended December 2025, Guardant Health reported revenue of $982.02M (+32.88% year over year). The net loss was $416.28M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +32.88%
- 2025 vs 2024
- Net margin
- -42.4%
- 2024: -59.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -57.8 | -65.6 | -26.4 | -35.4 | -60.3 | -62.7 | -64.5 | -51.1 | -94.0 | -30.3 | -78.7 | -77.8 |
| Depreciation and amortization | 9.6 | 9.4 | 10.1 | 9.4 | 10.0 | 10.2 | 10.5 | 10.6 | 10.6 | 10.7 | 10.9 | 11.0 |
| Capital expenditure | -11.8 | -5.6 | -27.8 | -10.4 | -5.6 | -4.5 | -18.9 | -4.2 | -5.1 | -6.9 | -4.1 | -2.4 |
| Investing cash flow | 101 | 699 | -905 | -14.4 | -10.6 | 303 | 10.5 | -295 | -5.1 | 28.1 | 663 | 261 |
| Financing cash flow | 23.0 | -21.6 | 732 | 4.3 | 1.6 | -66.9 | -2.9 | -2.9 | 5.9 | -1.1 | 90.6 | 3.8 |
| Share repurchases | -8.3 | -20.7 | -5.4 | -2.3 | -7.4 | -60.5 | -8.0 | -2.9 | -3.2 | -1.5 | -3.1 | -3.0 |
| Debt issued | 0.0 | 0.0 | 397 | 5.0 | 0.0 | — | — | — | — | — | — | — |
| Effect of exchange rates | -0.4 | -0.2 | -0.7 | -0.5 | 0.9 | 0.8 | -1.7 | 1.9 | -0.8 | -1.1 | 1.0 | -0.5 |
| Net change in cash | 66.3 | 612 | -200 | -46.0 | -68.4 | 174 | -58.6 | -347 | -94.0 | -4.4 | 676 | 186 |
| Free cash flow | -69.5 | -71.2 | -54.2 | -45.8 | -65.9 | -67.1 | -83.4 | -55.3 | -99.1 | -37.2 | -82.8 | -80.2 |
| Levered free cash flow | -24.7 | -37.5 | -1.8 | 89.6 | -136 | -40.2 | 60.0 | -17.2 | -72.8 | -119 | -48.9 | -35.2 |